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Noncardiac surgery (NCS) may be required within the first year after percutaneous coronary intervention (PCI) in
approximately 4% of patients and is the second most common reason for premature discontinuation of anti-
platelet therapy (APT),which may, in turn, increase the risk of perioperative ischemic events, particularly stent
thrombosis. Its continuation may increase the risk of perioperative bleeding. We review current information on
the incidence of these events, particularly related to APT, describe potentially useful strategies to minimize
the risks of adverse outcomes, and provide recommendations on APT use. (J Am Coll Cardiol 2012;60:
2005–16) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.062Percutaneous coronary intervention (PCI) is the most com-
mon strategy for myocardial revascularization, with more
than a million procedures performed annually in the United
States alone (1). Enthusiasm has been tempered by the
potentially lethal complication of stent thrombosis (ST) (2).
The most important ST predictor is premature discontinu-
ation of dual antiplatelet therapy (DAPT) (3,4). Apart from
noncompliance, the second most common reason for early
discontinuation of either DAPT or single antiplatelet ther-
apy (APT) is the need for noncardiac surgery (NCS),
accounting for one-third of cases (4).
In both retrospective (5) and prospective (6) studies,
approximately 4% of patients undergo NCS within the first
year after index PCI (approximately 40,000 patients in the
United States by current PCI usage). This large cohort
presents a challenge for the treating surgeon, anesthesiolo-
gist, and cardiologist in managing APT in the perioperative
period. On the basis of current American College of
Cardiology/American Heart Association guidelines, ap-
proximately two-thirds of all NCS procedures in the first
year after index PCI are classified as moderate to high risk
for major adverse cardiac events (MACE) (5–7). Surgical
stress creates a prothrombotic state due to increased platelet
activation and decreased fibrinolysis, explaining in part the
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(8–10).
The small, but persistent, ST risk long after PCI raises
the important issue of perioperative management. On the
one hand, MACE, particularly ST, is a concern after APT
discontinuation; with its continuation, bleeding looms as a
persistent danger. In this paper, we review studies of NCS
outcomes following PCI with either bare-metal stents
(BMS) or drug-eluting stents (DES), particularly in relation
to APT, and potential strategies to decrease these risks.
Methods
We performed a PubMed search for full-length articles
published within the last 10 years in the English language
(abstracts were excluded) with the following key terms:
“noncardiac surgery, coronary stent” and “noncardiac sur-
gery, percutaneous coronary intervention.” We identified 6
studies with BMS (11–16), 13 with DES (6,17–28), and 6
with both BMS and DES (5,29–33). In 1 study of 103
patients (34), stent type (BMS vs. DES) was unavailable in
75% of patients; we excluded this study except to discuss it
relative to anticoagulation strategies. Another paper was
excluded because the myocardial infarction (MI) endpoint,
although well defined, was not clearly presented (23). We
reviewed each study for definitions and incidence of MACE
and bleeding, APT status, and factors associated with
adverse outcomes. We also performed an extensive English
literature search for strategies to prevent MACE. In this
presentation, the ischemic risk of surgery was defined as “low,”
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the American College of Cardiol-
ogy/American Heart Association
guidelines (7).
Current guidelines for manage-
ment of patients undergoingNCS
after PCI. The 2009 American
College of Cardiology/American
Heart Association and 2010 Euro-
pean Society of Cardiology/Eu-
ropean Association of Cardio-
Thoracic Surgery guidelines provide
a framework for APT management
in the perioperative period following
PCI (7,35). Given the lack of pro-
spective randomized clinical trials,
recommendations are based primar-
ily on expert opinion and relatively
small, and mostly retrospective,
studies.
Four important variables cited
in decision making regarding APT use in the perioperative
period include urgency of surgery, PCI type (balloon angio-
plasty [BA] vs. stenting), stent type (DES vs. BMS), and
the duration between PCI and NCS.
Guidelines recommend that elective surgery be post-
poned for at least 2 weeks after BA, 1 month after BMS,
Abbreviations
and Acronyms
APT  antiplatelet therapy
ASA  aspirin
BA  balloon angioplasty
BMS  bare-metal stent(s)
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
LMWH  low-molecular-
weight heparin
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
NCS  noncardiac surgery
PCI  percutaneous
coronary intervention
ST  stent thrombosis
Limitations of Current StudiesTable 1 Limitations of Current Studies
First Author (Ref. #) Year
Small Sample Size
(N < 100) Retrospective
APT
We
Kaluza et al. (11) 2000  
Wilson et al. (12) 2003 
Sharma et al. (13) 2004  
Reddy et al. (14) 2005  
Brichon et al. (15) 2006  
Kim et al. (29) 2008 
Nuttal et al. (16) 2008 
Compton et al. (17) 2006  
Brotman et al. (18) 2006 
Conroy et al. (19) 2007  
Schouten et al. (30) 2007  
Rhee et al. (20) 2008 
Godet et al. (21) 2008 
Rabbitts et al. (22) 2008 
Anwaruddin et al. (25) 2009 
Assali et al. (26) 2009  
Van Kuijk et al. (31) 2009 
Choi et al. (23) 2010  
Chia et al. (24) 2010 
Berger et al. (6) 2010
Gandhi et al. (27) 2010 
Cruden et al. (5) 2010 
Brilakis et al. (28) 2011 
Albaladejo et al. (32) 2011
Brancati et al. (33) 2011   limitation present; APT  antiplatelet therapy; MACE  major adverse cardiac event(s); pts patienand 1 year after DES. The rationale relates to the time
frame for vascular healing and re-endothelialization in
animal studies (36). Current guidelines recommend that
aspirin (ASA) (81 to 325 mg/day) be continued through the
perioperative period if the risk of surgical bleeding is not
prohibitive. The decision regarding APT continuation with
urgent or emergent surgery is governed by the relative risks
of bleeding versus ST in an individual patient. This consid-
eration is reflected in the 2010 European Society of Cardi-
logy/European Association of Cardio-Thoracic Surgery
uidelines, where a “case by case” approach is suggested (35).
imitations of current guidelines and studies. Most pub-
ished studies are retrospective, single center, and/or with
mall sample size, limiting generalizability of the results
Table 1). In addition, definition of adverse events, both
ardiac and bleeding, details of perioperative APT, and
uration of post-operative monitoring vary, making com-
arisons among studies difficult. Thus, the reader must take
hese caveats into consideration in drawing conclusions
bout the risks and efficacy of APT in PCI patients
ndergoing NCS. In addition, current guidelines provide
PT recommendations for only the first year after PCI.
he small, but persistent, MACE risk including ST beyond
he first year is not addressed. Finally, it should be men-
ioned that MACE definitions vary in each study; thus, the
eader should refer to Tables 2 to 4 to determine what
constitutes MACE in each study.
Not
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NCS Following PCI With BMSTable 2 NCS Following PCI With BMS
First Author (Ref. #) Year N
Type of Surgery (%)
PCI to NCS
(days)
MACE APT in Periop Period (%) Major Bleeding
CommentsL I H C U Component (%) ASA P2Y12 Inh DAPT Component (%)
Kaluza et al. (11) 2000 40 33 65 2 13 D 20 5 12.5 2.5 Tx or reop 27 1. All MACE 2 weeks after PCI
MI 17.5 2. ST presumed to be cause of all MI
Wilson et al. (12) 2003 207 36 58 6 1–60 D, MI, ST, or
Revasc
4 51 14 26 “Excessive” surgical
site bleed
2
Tx 33
Sharma et al. (13) 2004 47 68 30 2 21 (n  27) D or MI 25 (21 days) NA 74 NA Tx 29 6 of 7 deaths in first 21 days
considered probable ST
21–90 (n  20) 15 (21–90 days) 70 Reop 0
Reddy et al. (14) 2005 56 10 60 20 10 42 MI or CVD 14 79* 32* Reop, Tx 2 PRBC,
Hb drop 2 g/dl
or IC, IO, or RP
bleed
5 All 3 bleeding episodes were in
patients receiving P2Y12 inhibitor
Brichon et al. (15) 2006 32 100 90 ST 9 66 0 0 Hemothorax or
RP bleed
10 30% of patients received only
heparin
Nuttal et al. (16) 2008 899 21 46 33 64 D, MI, ST, or
TLR
Overall: 5.2
30 days 10.5
30–90 days 3.8
90–365 days 2.8
64.5† Need for non-PRBC
Tx
5
*Percentage of patients taking both ASA and P2Y12 inhibitor not provided; †rates of individual or dual APT not provided.
ASA aspirin; BMS bare-metal stent(s); C cardiac; CABG coronary artery bypass grafting; cryo cryoprecipitate; CT clotting time; CVD cardiovascular death; D death; DAPT dual antiplatelet therapy; DES drug-eluting stent(s); FFP fresh frozen plasma;
H  high; Hb  hemoglobin; I  intermediate; IC  intracranial; inh  inhibitor; IO  intraocular; L  low; MI  myocardial infarction; NA  not available; NCS  noncardiac surgery; PCI  percutaneous coronary intervention; periop perioperative; plt  platelet;
post-op  post-operative; PRBC  packed red blood cells; P2Y12 inhibitor  thienopyridine; reop reoperation; RP  retroperitoneal; ST  stent thrombosis; TLR  target lesion revascularization; TVR  target vessel revascularization; Tx  transfusion; U  unknown.
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NCS Following PCI With DESTable 3 NCS Following PCI With DES
First Author
(Ref. #) Year N (n)
Type of Surgery (%)
PCI to
NCS
(days)
MACE APT in Periop Period (%) Major Bleeding
CommentsL I H C U Component (%) ASA
P2Y12
Inh DAPT Components (%)
Compton et al. (17) 2006 38 (59) 31 35 15 19 260 MI 0 83 40 * Post-op Tx 3
Brotman et al. (18) 2007 114 52 42 6 236 MI, ST, or D 1.8 1.8 0 21 Reop or IC or RP
bleed
0.9 No ST despite low
APT use
Conroy et al. (19) 2007 24 (42) NA Isch on ECG, trop
elev, or ST
7 NA 50 NA Surgical site
bleed or reop
2.4 1 LST, 2 VLST
(clopidogrel was
held in all)
Rhee et al. (20) 2008 141 96 4 228 ST 5 5 0 0 NA NA 7 days of P2Y12
inhibitor
discontinuation
was associated
with ST
Godet et al. (21) 2008 96 26 74 425 Trop elev 12 70 38 NA NA NA 26% of pts received
LMWH in periop
period
ST 2
Rabbitts et al. (22) 2008 520 18 56 25 204 D, MI, ST, or revasc 5.4 70 33 * Surgical site 1
1 yr  400 1 yr  6 “excessive bleed”
1 yr  12,0 1 yr  3.3
Chia et al. (24) 2010 710 348 MI or ST 1.5 14 9 18 NA NA
Anwaruddin et al. (25) 2009 481 (606) 5.6 55.6 20 22 390 10–ST (def  mod
prob)
2 15 1 21 NA NA Risk of MACE higher
if NCS 30 days
after PCI
20–D, nonfatal MI, ST
9
Assali et al. (26) 2009 78 81 19 414 MI, ST, or CD 7.7 18 42 21 Hb drop 2 g/dl 16.7 1) No difference in
MACE between
6–12 vs. 12
months
2) Most MACE
occurred 1
week after NCS
Berger et al. (6) 2010 206 76 20 4 179 CD, MI, or DST 1.9 NA NA NA NA NA
Gandhi et al. (27) 2011 135 (191) 23 62 15 547 DST 0.5 54 30 NA Bleeding with
hypotension,
blood loss
500 ml or
2 U PRBC Tx
6 APT was not
associated with
bleeding
complications
MI 2
Brilakis et al. (28) 2011 164 100 365 D, MI, or ST 0.6 NA NA NA NA NA
N (n) indicates the number of subjects (the number of noncardiac surgeries). *Percentage of patients taking both ASA and P2Y12 not provided.
def  definite; DST  definite stent thrombosis; Isch  ischemia; IV  intravenous; L  low; LMWH  low-molecular -weight heparin; LST  late stent thrombosis; mod prob  modified probable; revasc  revascularization; trop elev  troponin elevation; VLST very
late stent thrombosis; 10  primary; 20  secondary; other abbreviations as in Tables 1 and 2.
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NCS Following PCI With Either BMS or DESTable 4 NCS Following PCI With Either BMS or DES
First Author (Ref. #) Year
PCI to
NCS
(days)
MACE
Comments
n Type of Surgery (%)
Component
(%)
APT in Periop
Period (%) Major Bleeding
BMS DES L I H U BMS DES ASA I DAPT Component (%)
Kim et al. (29) 2008 101 138 NA CD, ST, or MI 0 2.2 NA NA NA NA NA Higher prevalence of
comorbidities in DES
group
Schouten et al. (30) 2007 93 99 12 60 23 5 730 MI or CD 2 3 53 (either single or
dual APT)
NA NA APT interruption was
associated with higher
MACE (5.5% vs. 0.0%,
p  0.023)
No difference in MACE
between BMS and DES
Van Kuijk et al. (31) 2009 174 376 33 51 15 BMS 1,314 D, MI, ST, or revasc 6 13 91* 9** Severe fatal, IC, reop, or
Tx of 4 units
10 (severe) Bleeding complications
significantly higher with
DAPT in both groups
31 47 22 DES 511 70* 30** Moderate  Tx of 1–3
units
8 (mod) Early NCS in either group was
associated with MACE
(overall p  0.001)
BMS  30 days  50% 30–
90 days  14%, and 90
days  4%
DES 30 days  35%, 30–
90 days  13%, 90–180
days  15%, 180–365
days  6% and 365
days  9%
Cruden et al. (5) 2010 1,383 570 19 71 10 BMS 503 10–in-hospital D 
ischemic cardiac
events
10–13.3 10–14.6 NA NA NA NA NA No significant difference
between BMS and DES
DES 371 20–In-hospital D 
MI
20–1.3 20–1.9 MACE higher if NCS 6
weeks vs 6 weeks after
PCI (42.4% vs. 12.8%,
p  0.001)
Albaladejo et al. (32) 2011 623 367 20 40 26 14 II MI, ST, HF, CS, SA, or
stroke
10.9† NA NA NA Major fatal, 2 unit Tx,
2 g/dl fall in Hb, IC,
IO, IS, Pe, RP, or need
for reop
9.5‡ Unknown stent type in 12.7%
Minor  Abnormal
bleeding as defined by
surgeon or physician
and not meeting
criteria for major
bleeding
Brancati et al. (33) 2011 70 31 26 65 9 0 288 D, MI, ST, or revasc 6 6 47* 36 Need for Tx or surgical
hemostasis
BMS 14
DES 619* 68
*Single APT either ASA or clopidogrel; **dual APT; †individual MACE rates not provided; ‡includes both major and minor bleed; §In 82.2% of individuals, interval between PCI and NCS was 1 year (median interval is not provided).
Abbreviations as in Table 2.
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Risk After Noncardiac Surgery in PCI Patients November 13, 2012:2005–16Cardiac risks from NCS in patients with prior PCI. NCS
FOLLOWING PCI WITH BMS. MACE following NCS with
MS was first reported by Kaluza et al. (11) who found a
7.5% (7 of 40) incidence of MI presumed to be secondary
o ST. Total mortality (ischemic  bleeding) was 20%. All
ACE occurred within the first 2 weeks after PCI.
ubsequent studies provide evidence that the high-risk
eriod for MACE may extend to 6 weeks, though the risk
eems to be lower between 3 to 6 weeks as compared with
he initial 2 weeks (12–14) (Fig. 1, Tables 2 to 5).
Nuttal et al. (16) in 899 patients showed an overall
ACE rate of 5.2%. APT (single vs. dual not specified)
as used perioperatively in 72% when the interval between
CI and NCS was 30 days and in approximately 60%
30 days. NCS within 1 month of PCI carried the highest
ACE risk (10.5%). The risk between 30 and 90 days was
.8%, with a persistent 2.8% risk between 90 and 360 days.
ther risk factors included general anesthesia (odds ratio:
.79, 95% confidence interval: 1.27 to 6.13, p  0.01) and
hock before the index PCI (odds ratio: 8.06, 95% confi-
ence interval: 3.53 to 18.41, p  0.001). A small study (32
atients) suggested that the high-risk period may extend to 3
onths because 2 of 3 ST occurred 30 days after PCI (15).
There are case reports of very late ST, that is, 1 year
rom BMS implantation following NCS; the incidence of
hese events, however, and their relationship to APT use is
ncertain (37–39).
NCS FOLLOWING PCI WITH DES. There is a wide variation in
he reportedMACErisk inDESpatients (Fig. 1, Tables 3 and 5).
Figure 1 The Incidence of MACE in Published Series
The reader should refer to Tables 2 to 4 for major adverse clinical events
(MACE) definition for each study. The time interval in days (d) between percuta-
neous coronary intervention (PCI) and noncardiac surgery (NCS) represents
either the mean or median time after NCS or the mid-point of the time range
as described in the individual study. The circle size approximates the study
sample size. Small modifications in circle size were made to allow graphical
representation. The exact sample sizes are described in Tables 2 to 4. The
colors of the circles represent the following: aqua  studies with bare-metal
stents (BMS) only; red  studies with drug-eluting stents (DES) only; lime 
BMS patients in studies with both BMS and DES stents; and pink  DES
patients in studies with both stent types.wo early studies suggested it was low (2%) (17,18). (hese studies were notable for a long interval between PCI
nd NCS (6 months), frequent APT use in the periop-
rative period (17), and relatively low-risk NCS. Similarly,
n a questionnaire-based study, a low MACE risk (1.5%)
as reported (24).
Other studies, however, suggest a higher MACE rate.
hee et al. (20) reported a 5% ST incidence following NCS
ithin 1 year of PCI. In this series, all oral APT agents were
ithheld. Assali et al. (26) identified a 7.7% MACE risk
ollowing NCS at least 6 months after PCI despite contin-
ation of single or dual APT in approximately 80% of cases.
The incidence of late ST (31 to 365 days after implan-
ation) in real-world practice in non-NCS patients is
pproximately 0.6% (40). A prospective registry reported 2%
ncidence of ST following NCS (21). In a single-center
etrospective study (N 520), MACE was 5.4% within the
rst year of PCI and 3.3% thereafter (22). There was no
ignificant MACE difference whether NCS was performed
90, 90 to 180, 181 to 360, or 365 days from PCI. There
as a significant univariate association between MACE and
dvanced age, emergent surgery, shock at index PCI, and
hienopyridine use in the perioperative period. However,
hienopyridine use was not associated with MACE after
djustment for emergency surgery. ASA was used within 7
ays of NCS in 70% of cases and thienopyridine in 33%,
hereas DAPT usage was not reported.
In another relatively large retrospective study (481 pa-
ients, 606 procedures), the risk of definite and probable ST
ith an average delay between PCI and surgery of about a
ear was 2% (25). ST risk was 6% if NCS was performed
ithin 1 month of PCI and 1.5% thereafter (p  0.04).
ther ST predictors were NCS being emergent, previous
I, pre-operative heparin use, and longer stent length.
SA and/or clopidogrel in the perioperative period was not
ssociated with either improved or worsened MACE risk.
In a prospective registry of 206 patients, MACE was
.9% (6). However, the incidence was 27 times higher if
CS was performed 1 week of index PCI as compared
ith any time period thereafter. A history of heart failure
nd serum creatinine 2.0 mg/dl also predicted MACE. In
he same registry, MACE associated with minor NCS
defined as surgery without a large surgical incision)1 year
fter DES was very low, with only 1 ST case in the first
eek following NCS among 164 subjects (28). APT status
as not described.
NCS beyond 1 year of index PCI may have a lower
ACE risk. A study of 135 DES patients undergoing 191
CS procedures with an average delay of 18 months had a
ow MACE rate (ST: 0.5%, MI: 2%) (27). ASA was
ontinued during the perioperative period in 54% and
lopidogrel in 30%. It was stated that there was no MACE
ifference between patients who received clopidogrel versus
ho did not, but the DAPT rates in the perioperative
eriod were not reported. Of all reported complications
ischemic  bleeding), 74% occurred within the first 3 days
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as carrying the highest MACE risk.
Individual very late ST cases with DES after NCS have been
described, but the incidence is uncertain (19,21,25,41–43).
NCS FOLLOWING PCI WITH EITHER BMS OR DES. The rel-
tive MACE incidence with BMS and DES following NCS
as been compared in a few studies (Tables 4 and 5). Cruden
et al. (5) compared BMS (n 1,383) withDES (n 570), with
median interval between PCI and NCS1 year. APT use
as not reported. MACE frequency was 13.3% for BMS
nd 14.6% with DES (p  0.3). High MACE rates in this
tudy likely reflected broad endpoint criteria (primary end-
oint: in-hospital death or ischemic cardiac event, ICD-10
International Classification of Diseases-10) codes 120.0,
20.1, 120.8–121.4, 121.9–122.1, 122.8, 122.9, 124.0, and
24.9–125.1; secondary endpoint: in-hospital death and
I, codes 121.0–121.4, 121.9–122.1, 122.8, and 122.9).
imilar, but smaller, studies have also failed to link MACE
isk to stent type (30,33). By contrast, a relatively small
tudy (BMS  101, DES  138) identified higher MACE
Incidence of ST After NCSTable 5 Incidence of ST After NCS
Thrombosis First Author (Ref. #) Patients
Bare-metal stent
Kaluza et al. (11) 40
Wilson et al. (12) 207
Sharma et al. (13) 47
Reddy et al. (14) 56
Brichon et al. (15) 32
Nuttal et al. (16) 899
Kim et al. (29) 101
Schouten et al. (30) 93
Van Kuijk et al. (31) 174
Brancati et al. (33) 71
Total 1,586
Drug-eluting stent
Compton et al. (17) 59
Brotman et al. (18) 114
Conroy et al. (19) 43
Rhee et al. (20) 141
Godet et al. (21) 96
Rabbitts et al. (22) 520
Chia et al. (24) 710
Anwaruddin et al. (25) 606
Assali et al. (26) 78
Berger et al. (6) 206
Gandhi et al. (27) 191
Brilakis et al. (28) 164
Kim et al. (29) 138
Schouten et al. (30) 99
Van Kuijk et al. (31) 376
Brancati et al. (33) 30
Total 3,571
Academic Research Consortium (ARC) definition of definite (def), probable (prob), or possible (poss)
note that many studies did not prospectively define ST by using ARC criteria; case descriptions wer
was defined as “ARC def.” The number in parenthesis is the number of patients in each ARC cate
Abbreviations as in Table 2.ith DES (2.2%) versus BMS (0%) (29), probably reflecting pigher baseline comorbidity in the DES cohort (increased
revalence of hypertension and diabetes mellitus, longer
tent length, and multivessel intervention) (29). In these
tudies, a short period (4 to 6 weeks) between PCI and
CS was associated with higher MACE regardless of stent
ype (31,33).
In a prospective multicenter observational study of 1,134
CS procedures (82% performed 1 year after PCI),
ACE risk was 10.9% (32). This study did not report
omplications by stent type. A multivariate analysis did
dentify complete APT interruption 5 days prior to NCS
s well as creatinine clearance 30 ml/min, pre-operative
emoglobin 10 g/dl, and urgent and high-risk surgery as
ignificant predictors for MACE.
Table 5 lists the incidence of ST in studies in which it was
pecifically stated. The apparently lower DES ST rate may
eflect a lack of studies during the very-high-risk period as
ompared with BMS studies, where many were performed
uring this time, as seen in Figure 1.
CS following BA. BA is rarely used as an isolated
N Definition of ST Incidence ST (%)
7 ARC def (2) or prob (5) 17.5
4 ND 1.93
7 ND 14.8
5 ARC def 8.9
3 ARC def 9.0
9 ARC def 1.0
0 0 0.0
2 ARC def 2.1
0 ND 0.0
4 ARC prob 5.63
41 ARC ST: def 21; prob 9; U 11 2.58*
0 ND 0.0
0 ARC def 0.0
3 ARC def 6.97
7 ARC def/prob/poss* 5.0
2 ARC def 2.0
4 ARC def 0.76
3 ARC def 0.42
11 ARC def (4) or prob (7) 2.0
2 ND 2.8
0 ARC def 0.0
1 ARC def 0.52
1 ND 0.6
3 ARC def (2) or prob (1) 2.17
2 ARC def 2.02
6 ND 1.59
2 ARC def 6.6
47 ARC ST: def 23; prob 8 U 16 1.31*
mber of stent thrombosis events; ND indicates ST not prospectively defined in theMethods. Please
fied by the authors into 1 of the categories. If coronary angiography was required for ST, this event
that study. *The results of this study did not allow for clarification of the ARC category.; n nu
e classirocedure. However, it may have some utility as a “holding”
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Risk After Noncardiac Surgery in PCI Patients November 13, 2012:2005–16procedure for NCS in certain circumstances. In a retrospec-
tive study of 350 patients undergoing NCS 2 months of
BA, Brilakis et al. (44) reported 3 adverse events (0.9%)
including one death and 2 MI. All events occurred among
the 188 patients undergoing NCS within 2 weeks of BA.
Aspirin was used in 78% and thienopyridine in 4%. Lei-
bowitz et al. (45) comparing BA (n  122) with stenting
(n  94) did not identify any significant difference in MACE
risk regardless of NCS timing (2 or 2 weeks). MI inci-
dence was 6% in the BA group. It should be noted that the
relatively high MI rate may have been related to the fact that
MACE incidence included events up to 6 months after NCS.
Figure 2 The Incidence of Bleeding Events
(A) The incidence of bleeding events and (B) the incidence of bleeding limited
to dual antiplatelet therapy (DAPT) in published series. The colors are as in
Figure 1 except purple (B) are studies with both BMS and DES. Abbreviations
as in Figure 1.
Incidence of Bleeding on Single APT or DPT After NCSTable 6 Incidence of Bleeding on Single APT or DPT After NCS
First Author (Ref. #)
Patient on DAPT
at Time of NCS
DAPT Patients
With Bleeding
DAPT Pati
With Bleedin
Kaluza et al. (11) 1 1 100.00
Wilson et al. (12) 54 1 1.85
Brotman et al. (18) 24 1 4.00
Assali et al. (26) 17 3 17.60
Van Kuijk et al. (31) 128 27 21.00
Total 224 33 14.70Abbreviations as in Tables 1 and 2.Risk of bleeding in the setting of NCS following PCI. It
is intuitive that APT, particularly DAPT, continued in the
perioperative period increases the bleeding risk, but the level
of risk remains uncertain.
Results from multiple studies report a variable frequency
of significant bleeding, in part due to different bleeding
endpoint definitions. Timing of NCS following PCI has
been variably associated with the bleeding risk with either
single APT or DAPT (Figs. 2A and 2B, Tables 2 to 4 and 6).
hough some studies (11,13) suggest higher bleeding risk if
CS is performed within 2 to 3 weeks of PCI, a large
etrospective study (16) did not identify any significant
ssociation, although there was a trend toward a higher
leeding risk if NCS was 30 days of PCI (30: 6.9%, 30 to
0: 4.6%, 90: 3.6%). In a prospective study of 103 stented
atients, there were only 4 major bleeding episodes, defined as
unusually high post-operative blood loss as assessed by the
urgeon” despite APT continuation (84% ASA, 44% clopi-
ogrel) or discontinuation for3 days, in addition to either the
se of unfractionated or low-molecular-weight heparin
LMWH) (34). Other retrospective studies also have not
dentified a significant relationship between APT use and with
he risk of perioperative bleeding (13,22).
There seems to be a higher bleeding risk with DAPT
ersus single APT, although very few studies, even retro-
pective ones, provide this comparison. Table 6 lists the
ncidence of bleeding in the perioperative period following
CS with the use of either single or dual APT. The mean
leeding risk from studies in which adequate information
as available was 4.1% for single APT versus 14.7% for
APT, driven in large part by the study of Van Kuijk et al.
31). They reported significant bleeding in 21% of DAPT
nd 4% of single APT patients (p  0.001). These results
iffer from the expected 1% increase in bleeding risk with
APT (vs. ASA alone) in the nonsurgical setting (46).
That being said, DAPT may have an acceptable bleeding
isk if future data provide evidence that there is a MACE
ecrease compared with DAPT discontinuation pre-
peratively. At least 1 surgical series suggests that DAPT
ay be used with an acceptable bleeding risk. In 108
on-PCI patients (47), the bleeding risk with limb ischemia
urgery in patients maintained on 75 mg of aspirin in the
erioperative period and then randomly assigned to either
lopidogrel or matched placebo was evaluated. There was no
Patients on Single APT
at Time of NCS
Single APT Patients
With Bleeding
Single APT Patients
With Bleeding (%)
— — —
134 1 0.7
2 0 0.0
47 7 15.0
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November 13, 2012:2005–16 Risk After Noncardiac Surgery in PCI Patientsincrease in major bleeding, but the transfusion requirement
was increased with DAPT (28%) versus ASA alone (12.6%)
(p 0.037). Though this study does not specifically address
atients with previous PCI undergoing NCS, it does pro-
ide evidence that DAPT may not increase major bleeding
ven in patients undergoing high-risk surgery.
Given the lack of large randomized studies, current
uidelines recommend a case-by-case approach, weighing
ACE versus bleeding risk (7,35).
trategies to reduce adverse cardiac ischemic complications in
tented patients following NCS. Given the high frequency
f NCS in the year after PCI and potential increase in
ACE (including ST) with both DES and BMS, it has
ecome imperative to develop better strategies to decrease
he risk of stent-related MACE. Potential strategies include
he following:
DAPT CONTINUATION IN THE PERIOPERATIVE PERIOD. DAPT
ontinuation in the perioperative period is 1 strategy to
revent or reduce MACE. As previously noted, ASA is
ecommended by guidelines unless the bleeding risk is
Figure 3 A Guide to APT in the Perioperative Period
The illustration uses a “case-by-case” approach. *High-risk period is 4 weeks af
angioplasty; N  no; Y  yes; other abbreviations as in Figures 1 and 2.rohibitive. It should be noted that there have been con- dicting data from previous studies whether DAPT contin-
ation is actually effective in preventing ST and/or MACE
please see the preceding text). Current data suggest that
inor bleeding and bleeding severe enough to warrant
ransfusion may be more frequent with DAPT, but major or
ife-threatening bleeds, depending on the bleeding defini-
ion, may not be more frequent. Therefore, adoption of
APT as a “fallback” position for NCS in patients who
ave an “acceptable” pre-operative bleeding risk may im-
rove cardiac outcomes. Further data are required to deter-
ine whether such a fallback position carries a favorable
isk–benefit ratio.
We provide a suggested approach to APT use in Figure 3.
t assumes that APT, and particularly DAPT, decrease
ACE and ST and increase perioperative bleeding. The
ow diagram is presented as a suggested approach for the
linician to individualize treatment in the absence of defin-
tive data.
HEPARIN AND LMWH. ST prevention likely requires some
nt implantation. APT  antiplatelet therapy; ASA  aspirin; BA  balloonter steegree of platelet inhibition. Thus, it remains unclear
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Risk After Noncardiac Surgery in PCI Patients November 13, 2012:2005–16whether DAPT cessation and anticoagulation therapy alone
is a useful strategy. A 103-patient study (unknown stent
type: 77%) undergoing NCS 1 year after PCI evaluated
addition of either unfractionated or LMWH perioperatively
in addition to continuation of some type of APT (ASA
85%, clopidogrel 44%) (34). Though the incidence of
significant bleeding was low, the risk of overall adverse
events was high (approximately 44%), likely due in part to
the primary composite endpoint definition that included
cardiac death, MI, revascularization (PCI or coronary artery
bypass grafting), congestive heart failure, unstable angina,
significant arrhythmias, biochemical evidence of myocardial
necrosis, sepsis, surgical bleeding, and nonsurgically related
bleeding. Given the paucity of data, the value of heparin or
LMWH is uncertain, and further data are required.
INTRAVENOUS GLYCOPROTEIN IIB/IIIA THERAPY. DAPT
discontinuation preoperatively and use of a short-acting
intravenous APT in addition to ASA is another potential
strategy. Savonitto et al. (48) used tirofiban in 30 DES
patients undergoing urgent surgery 1 year after DES
implantation. Clopidogrel was stopped 5 days pre-
operatively and tirofiban continued up to 4 h before surgery.
There was no MACE and only 1 major bleeding episode.
This study may have underestimated the bleeding risk
because patients with high baseline bleeding risk were
excluded. A similar protocol was tested in 36 DES patients
(ASA continued in 80%) undergoing cardiac surgery (n 
15) or NCS (n  21) (49). There was no MACE and 6
leeding episodes (5 transfusions, 1 re-operation). Based on
hese small studies, a “bridging strategy” using short-acting
ntravenous APT may be an alternative to prevent MACE
n high-risk patients, but further data are required.
ewer antiplatelet agents and NCS. The TIMI-38
Thrombolysis In Myocardial Infarction 38) trial demon-
trated that in acute coronary syndrome patients, prasugrel
ad a lower ST risk versus clopidogrel, whereas bleeding
omplications were more frequent (50). Although there are
o studies of prasugrel in the NCS setting, the same
onsiderations as with clopidogrel regarding bleeding com-
lications are applicable. Because of its longer half-life, it is
ecommended to withhold prasugrel 7 days before surgery.
Ticagrelor is a reversible P2Y12 inhibitor that has been
hown to compare favorably with clopidogrel in terms of
oth efficacy and safety (51). This agent may be useful during
CS because it is reversible and has a rapid onset of action;
owever, its action offset may be as long as 5 to 7 days and thus
oes not appear to offer an advantage over other P2Y12
inhibitors in allowing NCS with a minimal break in platelet
inhibition from an oral agent (52). At present, there are no
published data in patients undergoing NCS.
Cangrelor, currently investigational, is an intravenous
non-thienopyridine P2Y12 receptor inhibitor, with a 3-min
half-life (52). The recently reported BRIDGE (Bridging
Anticoagulation in Patients who Require Temporary Inter-
ruption of Warfarin Therapy for an Elective InvasiveProcedure or Surgery) trial (53) demonstrated that cangrelor
could provide adequate platelet inhibition before surgery
after oral thienopyridine discontinuation. Bleeding events
were not increased in patients who received cangrelor
compared with placebo nor was there any difference in
ischemic events. It should be noted that at the time of
surgery, the cangrelor group did not demonstrate any
difference in platelet inhibition compared with placebo; as
such, the BRIDGE study showed a means to maintain
platelet inhibition before, but not during, surgery. Cangre-
lor’s value in reducing MACE with an acceptable bleeding
risk during surgery requires a large-scale randomized study.
Conclusions and Recommendations
The current, rather limited, data suggest the following
regarding the MACE and bleeding risks after NCS, and
methods to decrease them:
1. The actual MACE risk after NCS remains uncertain,
with wide variations reported (Fig. 1, Tables 2 to 5).
There does seem to be a consensus, however, that the
highest-risk period for ST after PCI with either BMS
or DES following NCS is the first 4 weeks. Therefore,
it seems reasonable to withhold NCS, if possible, for
at least 4 weeks after PCI.
2. In the non-NCS situation, it is recommended that
DAPT be continued for 1 to 12 months with BMS
and at least 12 months for DES. Should NCS be
required during this period, consideration to continue
DAPT during NCS should be given, understanding that
the risks and benefits of such an approach remain unclear
based on current data (Fig. 3). However, it seems
reasonable until more definitive data are forthcoming to
recommend ASA in most cases as per guidelines unless
the risk of bleeding is prohibitive and to recommend
DAPT when the risk of bleeding is less than severe.
3. An important issue that has emerged is the persistent
MACE risk even beyond the conventional “high-risk”
period. The value of APT is uncertain. It seems
reasonable to consider ASA unless the risk of bleeding
is more than moderate, although further data are
required to strengthen this recommendation.
4. The frequency of the combination of prior stent
implantation and NCS recommends a randomized
prospective trial to determine whether, and to what
extent, APT, either single or dual, affects MACE, ST,
and bleeding incidence after NCS.
5. At present, decision making regarding APT in the
perioperative period in an individual patient will have
to balance bleeding versus MACE risk. Recent strat-
egies evaluating use of glycoprotein IIb/IIIa inhibitor
or newer P2Y12 receptor antagonists look promising,
but further studies are required. A coordinated treat-
ment plan by the cardiologist, anesthesiologist, and
surgeon is essential.
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